Overview

Gender

female

Amy Grahn is Senior Vice President, Clinical Development and Operations at Horizon Pharma. Ms. Grahn has more than 20 years of pharmaceutical industry experience spanning pre-clinical research to commercial roles, with a primary focus on clinical operations. She was most recently vice president of clinical operations at MedGenesis Therapeutix Inc. in British Columbia, Canada, where she was responsible for strategic planning, development and implementation of clinical and pre-clinical development plans for therapeutic agents delivered via the MedGenesis convection-enhanced delivery (CED) platform.


Ms. Grahn served as vice president of clinical operations at NeoPharm where she was responsible for the Company’s lead compound, IL13-PE38 (under a CRADA with FDA) for recurrent glioblastoma mulitforme, from Phase 1 to completion of Phase 3 in five years. In addition, Ms. Grahn oversaw the progression of two additional compounds from Phase 1 to Phase 2.

During her career, Ms. Grahn has also held various senior level positions at Takeda Pharmaceuticals North America, Inc., Searle and Abbott. She has a master’s degree in biochemistry from Illinois Institute of Technology in Chicago and a bachelor’s degree in chemistry and biology from Knox College in
Galesburg, IL.